Navigation Links
Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program

ALBUQUERQUE, N.M., Dec. 21, 2010 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, today announced that it has been awarded $400,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.  Proceeds from the grants will be used to advance the development of biomarker studies underway, one of which is to determine patient responsiveness to anti-TNF therapy, a drug used to treat inflammatory diseases such as Inflammatory Bowel Disease (IBD) and its sub-types, Ulcerative Colitis (UC) and Crohn's Disease (CD).

Genomic tests are becoming an integral component of accurate disease prevention, risk evaluation, diagnosis, management, and treatment.  Laboratories such as Exagen play a critical role in bringing novel molecular genomic tests to the medical community.

"This award recognizes Exagen's unique discovery and development efforts in molecular diagnostics," said Scott Glenn, Exagen CEO.  "Our anti-TNF discovery will lead to targeted treatment options for GI, Rheumatoid Arthritis, and Psoriasis patients with chronic inflammation.  Our research may also provide insight into targeted dosing levels, drug intervals, and drug options—all of which today are optimized through trial and error."

Exagen recently launched its initial suite of internally developed molecular diagnostic tests for IBD, UC, CD, and Irritable Bowel Syndrome.  Until these tests were delivered to the market, no genetic testing was available for these disease states. The most widely used tests were serology-based with sensitivities of 51 to 74%.  The Exagen molecular diagnostic tests achieve 84 to 92% sensitivity.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed diagnostic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit

SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
2. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
3. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
4. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
5. The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine
6. bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
7. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
8. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
9. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
10. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
11. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Frost & Sullivan is ... program addresses ways companies can innovate and transform ... --> ... --> ... well as the disrupting factors altering the industry, ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "2016 ... Sales Forecasts, Innovative Technologies, Competitive Strategies, Opportunities ... report to their offering. --> ... the "2016 Europe Cell Surface Markers: ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces that its best selling system laboratory animal colony management software solution, ezColony®, ... without investing in on-site IT resources., , Many organizations ...
(Date:12/1/2015)... SUNNYVALE, Calif. , Dec. 1, 2015 ... part of its participation at the Piper Jaffray Healthcare ... later this morning, the Company is reaffirming its outlook ... guidance for 2016, in addition to discussing longer term ... Chairman and Chief Executive Officer.  "We continue to be ...
Breaking Biology Technology:
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
Breaking Biology News(10 mins):